
-
ORIC Pharmaceuticals NasdaqGS:ORIC ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Location: 240 East Grand Avenue, 2Nd Floor, South San Francisco, CA, 94080, United States | Website: https://www.oricpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
141.2M
Cash
203.7M
Avg Qtr Burn
-28.75M
Short % of Float
21.35%
Insider Ownership
9.56%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORIC-114 Details Cancer, 1L Non-small cell lung carcinoma | Phase 3 Initiation | |
ORIC-114 Details Solid tumor/s, Advanced malignancies, Cancer | Phase 1b Data readout | |
ORIC-944 Details Prostate cancer, Cancer | Phase 1b Data readout | |
ORIC-533 Details Multiple myeloma, Cancer | Phase 1b Update | |
ORIC-101 + Xtandi (enzalutamide) Details Prostate cancer, Cancer | Failed Discontinued | |
ORIC-101 and nab-paclitaxel Details Solid tumor/s, Muscle control disorder, Spasticity, Cancer | Failed Discontinued |